JAZZ

Jazz Pharmaceuticals plc

107.85 USD
+0.49 (+0.46%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Jazz Pharmaceuticals plc stock is up 3.76% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 58.82% of the previous 17 June’s closed higher than May. In the last 9 Unusual Options Trades, there were 3 PUTs, 6 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
15 May 16:59 21 Jun, 2024 110.00 PUT 68 129
15 May 17:25 21 Jun, 2024 110.00 PUT 89 129
22 May 17:04 20 Sep, 2024 115.00 CALL 100 98
22 May 17:04 20 Sep, 2024 115.00 CALL 200 98
24 May 14:13 20 Sep, 2024 115.00 CALL 203 318
24 May 19:51 19 Jul, 2024 115.00 CALL 100 0
05 Jun 18:36 21 Mar, 2025 115.00 CALL 28 0
07 Jun 19:38 21 Jun, 2024 110.00 CALL 65 147
20 Jun 13:33 20 Dec, 2024 120.00 PUT 20 287

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc identifies, develops, commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi, Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the. treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for. adults with newly-diagn

  • Needham
    Thu Jun 20, 11:19
    buy
    confirm
  • Goldman Sachs
    Wed Jun 5, 08:23
    buy
    initial